Lux Biosciences

About:

Lux Biosciences is a biotechnology company developing medicines for the treatment of ophthalmic diseases.

Top Investors: Novo Holdings, SV Health Investors, HBM Healthcare Investments, Prospect Venture Partners

Description:

Lux Biosciences, Inc., a biotechnology company, develops medications to treat ophthalmic diseases. Its products include LX201, a silicone matrix ocular implant that enables the release of cyclosporine A to the eye for one year; Luveniq, an oral form of calcineurin inhibitor voclosporin; LX212, a bioerodible polymer implant that contains voclosporin; and LX214, a topical mixed nanomicellar formulation of voclosporin therapy for dry eyes. The company was founded in 2005 and is based in Jersey City, New Jersey.

Total Funding Amount:

$129M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Jersey City, New Jersey, United States

Founded Date:

2005-01-01

Contact Email:

bd(AT)luxbio.com

Founders:

Clarke Atwell, Eddy Anglade, Sidney L. Weiss, Ulrich Grau

Number of Employees:

11-50

Last Funding Date:

2012-03-06

IPO Status:

Private

Industries: